Targeting a protein to improve eye surface health
Official title: Clusterin Targeting of Ocular Surface Disease
Funded at Proteris Biotech, INC. · NIH-10695646 · Data updated 2026-11-12
This study is looking at how a special protein called clusterin can help treat dry eye syndrome by using eye drops to soothe and heal the surface of your eyes, making them feel better and healthier.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Proteris Biotech, INC. NIH-funded |
| Lab location | 1 site (Glendale, UNITED STATES) |
| Project start | September 30, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $294,662 |
| NIH project number | 1R41EY034396-01A1 |
| Project ID | NIH-10695646 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing symptoms of dry eye syndrome, particularly those with aqueous-deficient subtypes.
✕Less likely to help
Patients with ocular surface diseases not related to dry eye syndrome may not benefit from this research.
What this research studies
This research investigates the role of clusterin, a protective protein, in treating ocular surface diseases, particularly dry eye syndrome. The approach involves understanding how clusterin can help repair and protect the cells on the eye's surface that are damaged due to tear dysfunction. By potentially delivering clusterin through eye drops, the research aims to reduce inflammation and promote healing of the ocular surface. Patients may be monitored for improvements in symptoms and overall eye health as part of the research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the quality of life for patients suffering from dry eye syndrome.
How similar studies have gone: Previous research has shown promise in using similar protective proteins for ocular surface health, indicating a potential for success in this approach.
Where this research is happening
-
Proteris Biotech, INC.
Glendale, United States Active
Researchers
- Principal investigator: Fini, M Elizabeth — Proteris Biotech, INC.
- Study coordinator: Fini, M Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.